Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.
Nurden
A T
AT
UMR 5533 CNRS and the Unité des Soins Intensifs (C.D.-J.), Institut Fédératif de Recherche "Coeur-Vaisseaux-Thrombose," Hôpital Cardiologique, Pessac, France. Alan.Nurden@cnrsh.u-bordeaux2.fr
Poujol
C
C
Durrieu-Jais
C
C
Nurden
P
P
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000276:immunology; D013927:Thrombosis / Q000628:therapy*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab